Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer
Conclusion
When economic models are based on clinical trial data, many inputs and outcomes are held consistent. The alterable inputs were not in and of themselves large enough to significantly impact the results between countries, which were directionally consistent with greater variation seen in sensitivity analyses. The factors that vary across jurisdictions, even when minor, can have an impact on trial-based economic analyses.
Funding
Eli Lilly and Company.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Alimta | Avastin | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Health | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology